GSK targets Syndivia’s prostate cancer ADC in £268m buy - Pharmaceutical Technology
GSK Acquires Syndivia's Prostate Cancer ADC Despite having its own ADC in development for prostate cancer, GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (AD…